Streetbeat News

Products Services

COWN

Crescent Biopharma is set to present at the TD Cowen 45th Annual Health Care Conference, focusing on their lead program CR-001, a bispecific antibody for solid tumors.

Portfolio Pulse from

February 26, 2025 | 1:15 pm

CAVA

Cava CEO Brett Schulman discussed the company's Q4 earnings, emphasizing a long-term focus over short-term results. The discussion included the 2025 outlook and potential tariff impacts.

Portfolio Pulse from

February 26, 2025 | 1:00 pm

AXON

Axon reported better-than-expected fourth-quarter earnings, driven by increased adoption of its electroshock weapons and VR technologies. This positive earnings report led to a rise in Axon's stock price.

Portfolio Pulse from

February 26, 2025 | 1:00 pm

AVGO

SOUN

The article compares SoundHound AI and Broadcom as potential AI stock investments. AI is expected to significantly boost the global economy by 2030.

Portfolio Pulse from

February 26, 2025 | 1:00 pm

WGRX

Wellgistics Health, Inc. (NASDAQ: WGRX) has announced an agreement with Tollo Health to market Tollo's medical food products targeting GLP-1 treatment side effects and Long COVID. This includes products like Galectovid™ for managing viral infections.

Portfolio Pulse from

February 26, 2025 | 1:00 pm

SUPN

Supernus Pharmaceuticals, Inc. is under investigation by Levi & Korsinsky for potential federal securities law violations after its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint.

Portfolio Pulse from

February 26, 2025 | 1:00 pm

BCRX

BioCryst Pharmaceuticals' stock has risen 9% since September due to strong Orladeyo sales and increased revenue guidance for 2025. Orladeyo's market presence is solidified by its convenience and exclusivity until 2035, despite potential competition from Pharvaris' deucrictibant.

Portfolio Pulse from

February 26, 2025 | 1:00 pm

JNPR

Juniper Networks has launched a new solution designed for GPUaaS and AIaaS providers, aimed at accelerating AI delivery and simplifying operations. This solution is expected to enhance performance and reduce costs for AI cloud providers.

Portfolio Pulse from

February 26, 2025 | 1:00 pm

PHIO

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) will participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series on March 5, 2025. The company focuses on developing therapeutics using its INTASYL® siRNA gene silencing technology to enhance immune cell effectiveness against cancer.

Portfolio Pulse from

February 26, 2025 | 1:00 pm

LLY

NVO

The GLP-1 industry is dominated by Novo Nordisk and Eli Lilly, as compounding facilities stop making compounded versions of their drugs. This could strengthen their market position.

Portfolio Pulse from

February 26, 2025 | 1:00 pm